FutureSenseIndia

DRREDDY Q2 Results: Revenue rose by 16.00% year-over-year (YoY) to Rs. 8038 crore, while net profit declined by 10.00% YoY to Rs. 1342 crore.

NSE: DRREDDY: Rs.1,276.90 (+0.68%)

Dr. Reddy’s Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.

Revenue

Revenue for the current quarter (Sep 2024) is Rs. 8038 crore which is Rs. 7696 crore more than the revenue in the previous quarter (Jun 2024). However, it is higher than the revenue for the same quarter last year (Sep 2023) which was Rs. 6903 crore.

Net Profit

Net Profit for the current quarter (Sep 2024) is Rs. 1342 crore, which is Rs. 1392 crore less than the net profit in the previous quarter (Jun 2024). However, compared to the same quarter last year, it is significantly lower than the net profit of Rs. 1482 crore for Sep 2023.

EPS

The EPS for the current quarter (Sep 2024) is 15, which is 16 less than the EPS for the previous quarter (Jun 2024). However, compared to the same quarter last year, it is lower than EPS of 17 for Sep 2023.

Other Income

Other income for the current quarter (Sep 2024) is Rs. 314 crore, which is Rs. 193 crore more than the other income for the previous quarter (Jun 2024). However, compared to the same quarter last year, it is lower than the other income of Rs. 319 crore for Sep 2023.

Leave a Reply

Your email address will not be published. Required fields are marked *